International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study)
Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless of the International Metastatic RCC Database Consortium (IMDC) risk category, even tho...
Saved in:
| Published in | BMC cancer Vol. 24; no. 1; pp. 757 - 5 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
24.06.2024
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless of the International Metastatic RCC Database Consortium (IMDC) risk category, even though TKI monotherapy is still a therapeutic option in selected patients. However, comparisons between the different first-line treatment strategies are lacking and few real-world data are available in this setting. For this reason, the regimen choice represents an important issue in clinical practice and the optimal treatment sequence remains unclear.
The REGAL study is a multicentric prospective observational study enrolling mRCC patients treated with first-line systemic therapy according to clinical practice in a real-world setting. A retrospective cohort of mRCC patients who received first-line systemic therapy from the 1st of January 2021 will also be included. The primary objective is to identify potential prognostic and predictive factors that could help guide the treatment choice; secondary objectives included the assessment of the prognostic performance of the novel prognostic Meet-URO score (IMDC score + neutrophil-to-lymphocyte ratio + bone metastases) compared with the IMDC score and the comparison between treatment strategies according to response and survival outcomes and toxicity profile.
Considering the high number of therapeutic first-line strategies available for mRCC, the identification of clinical prognostic and predictive factors to candidate patients to a preferable systemic therapy is still an unmet clinical need. The Meet-URO 33 study aims to provide a large-scale real-world database on mRCC patients, to identify the clinical predictive and prognostic factors and the different performances between the ICI-based combinations according to response, survival and toxicity.
CESC IOV 2023-78. |
|---|---|
| AbstractList | Abstract Background Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless of the International Metastatic RCC Database Consortium (IMDC) risk category, even though TKI monotherapy is still a therapeutic option in selected patients. However, comparisons between the different first-line treatment strategies are lacking and few real-world data are available in this setting. For this reason, the regimen choice represents an important issue in clinical practice and the optimal treatment sequence remains unclear. Methods The REGAL study is a multicentric prospective observational study enrolling mRCC patients treated with first-line systemic therapy according to clinical practice in a real-world setting. A retrospective cohort of mRCC patients who received first-line systemic therapy from the 1st of January 2021 will also be included. The primary objective is to identify potential prognostic and predictive factors that could help guide the treatment choice; secondary objectives included the assessment of the prognostic performance of the novel prognostic Meet-URO score (IMDC score + neutrophil-to-lymphocyte ratio + bone metastases) compared with the IMDC score and the comparison between treatment strategies according to response and survival outcomes and toxicity profile. Discussion Considering the high number of therapeutic first-line strategies available for mRCC, the identification of clinical prognostic and predictive factors to candidate patients to a preferable systemic therapy is still an unmet clinical need. The Meet-URO 33 study aims to provide a large-scale real-world database on mRCC patients, to identify the clinical predictive and prognostic factors and the different performances between the ICI-based combinations according to response, survival and toxicity. Trial Registration CESC IOV 2023-78. Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless of the International Metastatic RCC Database Consortium (IMDC) risk category, even though TKI monotherapy is still a therapeutic option in selected patients. However, comparisons between the different first-line treatment strategies are lacking and few real-world data are available in this setting. For this reason, the regimen choice represents an important issue in clinical practice and the optimal treatment sequence remains unclear.BACKGROUNDNowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless of the International Metastatic RCC Database Consortium (IMDC) risk category, even though TKI monotherapy is still a therapeutic option in selected patients. However, comparisons between the different first-line treatment strategies are lacking and few real-world data are available in this setting. For this reason, the regimen choice represents an important issue in clinical practice and the optimal treatment sequence remains unclear.The REGAL study is a multicentric prospective observational study enrolling mRCC patients treated with first-line systemic therapy according to clinical practice in a real-world setting. A retrospective cohort of mRCC patients who received first-line systemic therapy from the 1st of January 2021 will also be included. The primary objective is to identify potential prognostic and predictive factors that could help guide the treatment choice; secondary objectives included the assessment of the prognostic performance of the novel prognostic Meet-URO score (IMDC score + neutrophil-to-lymphocyte ratio + bone metastases) compared with the IMDC score and the comparison between treatment strategies according to response and survival outcomes and toxicity profile.METHODSThe REGAL study is a multicentric prospective observational study enrolling mRCC patients treated with first-line systemic therapy according to clinical practice in a real-world setting. A retrospective cohort of mRCC patients who received first-line systemic therapy from the 1st of January 2021 will also be included. The primary objective is to identify potential prognostic and predictive factors that could help guide the treatment choice; secondary objectives included the assessment of the prognostic performance of the novel prognostic Meet-URO score (IMDC score + neutrophil-to-lymphocyte ratio + bone metastases) compared with the IMDC score and the comparison between treatment strategies according to response and survival outcomes and toxicity profile.Considering the high number of therapeutic first-line strategies available for mRCC, the identification of clinical prognostic and predictive factors to candidate patients to a preferable systemic therapy is still an unmet clinical need. The Meet-URO 33 study aims to provide a large-scale real-world database on mRCC patients, to identify the clinical predictive and prognostic factors and the different performances between the ICI-based combinations according to response, survival and toxicity.DISCUSSIONConsidering the high number of therapeutic first-line strategies available for mRCC, the identification of clinical prognostic and predictive factors to candidate patients to a preferable systemic therapy is still an unmet clinical need. The Meet-URO 33 study aims to provide a large-scale real-world database on mRCC patients, to identify the clinical predictive and prognostic factors and the different performances between the ICI-based combinations according to response, survival and toxicity.CESC IOV 2023-78.TRIAL REGISTRATIONCESC IOV 2023-78. BackgroundNowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless of the International Metastatic RCC Database Consortium (IMDC) risk category, even though TKI monotherapy is still a therapeutic option in selected patients. However, comparisons between the different first-line treatment strategies are lacking and few real-world data are available in this setting. For this reason, the regimen choice represents an important issue in clinical practice and the optimal treatment sequence remains unclear.MethodsThe REGAL study is a multicentric prospective observational study enrolling mRCC patients treated with first-line systemic therapy according to clinical practice in a real-world setting. A retrospective cohort of mRCC patients who received first-line systemic therapy from the 1st of January 2021 will also be included. The primary objective is to identify potential prognostic and predictive factors that could help guide the treatment choice; secondary objectives included the assessment of the prognostic performance of the novel prognostic Meet-URO score (IMDC score + neutrophil-to-lymphocyte ratio + bone metastases) compared with the IMDC score and the comparison between treatment strategies according to response and survival outcomes and toxicity profile.DiscussionConsidering the high number of therapeutic first-line strategies available for mRCC, the identification of clinical prognostic and predictive factors to candidate patients to a preferable systemic therapy is still an unmet clinical need. The Meet-URO 33 study aims to provide a large-scale real-world database on mRCC patients, to identify the clinical predictive and prognostic factors and the different performances between the ICI-based combinations according to response, survival and toxicity.Trial RegistrationCESC IOV 2023-78. Background Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless of the International Metastatic RCC Database Consortium (IMDC) risk category, even though TKI monotherapy is still a therapeutic option in selected patients. However, comparisons between the different first-line treatment strategies are lacking and few real-world data are available in this setting. For this reason, the regimen choice represents an important issue in clinical practice and the optimal treatment sequence remains unclear. Methods The REGAL study is a multicentric prospective observational study enrolling mRCC patients treated with first-line systemic therapy according to clinical practice in a real-world setting. A retrospective cohort of mRCC patients who received first-line systemic therapy from the 1st of January 2021 will also be included. The primary objective is to identify potential prognostic and predictive factors that could help guide the treatment choice; secondary objectives included the assessment of the prognostic performance of the novel prognostic Meet-URO score (IMDC score + neutrophil-to-lymphocyte ratio + bone metastases) compared with the IMDC score and the comparison between treatment strategies according to response and survival outcomes and toxicity profile. Discussion Considering the high number of therapeutic first-line strategies available for mRCC, the identification of clinical prognostic and predictive factors to candidate patients to a preferable systemic therapy is still an unmet clinical need. The Meet-URO 33 study aims to provide a large-scale real-world database on mRCC patients, to identify the clinical predictive and prognostic factors and the different performances between the ICI-based combinations according to response, survival and toxicity. Trial Registration CESC IOV 2023-78. Keywords: Metastatic renal cell carcinoma, Immunotherapy, Immune checkpoint inhibitor, Clinical practice, Real-world, IMDC score, Meet-URO score, Prospective, Retrospective Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless of the International Metastatic RCC Database Consortium (IMDC) risk category, even though TKI monotherapy is still a therapeutic option in selected patients. However, comparisons between the different first-line treatment strategies are lacking and few real-world data are available in this setting. For this reason, the regimen choice represents an important issue in clinical practice and the optimal treatment sequence remains unclear. The REGAL study is a multicentric prospective observational study enrolling mRCC patients treated with first-line systemic therapy according to clinical practice in a real-world setting. A retrospective cohort of mRCC patients who received first-line systemic therapy from the 1st of January 2021 will also be included. The primary objective is to identify potential prognostic and predictive factors that could help guide the treatment choice; secondary objectives included the assessment of the prognostic performance of the novel prognostic Meet-URO score (IMDC score + neutrophil-to-lymphocyte ratio + bone metastases) compared with the IMDC score and the comparison between treatment strategies according to response and survival outcomes and toxicity profile. Considering the high number of therapeutic first-line strategies available for mRCC, the identification of clinical prognostic and predictive factors to candidate patients to a preferable systemic therapy is still an unmet clinical need. The Meet-URO 33 study aims to provide a large-scale real-world database on mRCC patients, to identify the clinical predictive and prognostic factors and the different performances between the ICI-based combinations according to response, survival and toxicity. CESC IOV 2023-78. Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless of the International Metastatic RCC Database Consortium (IMDC) risk category, even though TKI monotherapy is still a therapeutic option in selected patients. However, comparisons between the different first-line treatment strategies are lacking and few real-world data are available in this setting. For this reason, the regimen choice represents an important issue in clinical practice and the optimal treatment sequence remains unclear. The REGAL study is a multicentric prospective observational study enrolling mRCC patients treated with first-line systemic therapy according to clinical practice in a real-world setting. A retrospective cohort of mRCC patients who received first-line systemic therapy from the 1st of January 2021 will also be included. The primary objective is to identify potential prognostic and predictive factors that could help guide the treatment choice; secondary objectives included the assessment of the prognostic performance of the novel prognostic Meet-URO score (IMDC score + neutrophil-to-lymphocyte ratio + bone metastases) compared with the IMDC score and the comparison between treatment strategies according to response and survival outcomes and toxicity profile. Considering the high number of therapeutic first-line strategies available for mRCC, the identification of clinical prognostic and predictive factors to candidate patients to a preferable systemic therapy is still an unmet clinical need. The Meet-URO 33 study aims to provide a large-scale real-world database on mRCC patients, to identify the clinical predictive and prognostic factors and the different performances between the ICI-based combinations according to response, survival and toxicity. |
| ArticleNumber | 757 |
| Audience | Academic |
| Author | Procopio, Giuseppe Bimbatti, Davide Rebuzzi, Sara Elena Fornarini, Giuseppe Buti, Sebastiano Messina, Carlo Basso, Umberto Rescigno, Pasquale Banna, Giuseppe Luigi Maruzzo, Marco Naglieri, Emanuele Pignata, Sandro De Giorgi, Ugo Signori, Alessio Mattana, Alvise |
| Author_xml | – sequence: 1 givenname: Sara Elena surname: Rebuzzi fullname: Rebuzzi, Sara Elena organization: Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy – sequence: 2 givenname: Giuseppe surname: Fornarini fullname: Fornarini, Giuseppe organization: Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy – sequence: 3 givenname: Alessio surname: Signori fullname: Signori, Alessio organization: Department of Health Sciences (DISSAL), Section of Biostatistics, University of Genova, Genova, Italy – sequence: 4 givenname: Sebastiano surname: Buti fullname: Buti, Sebastiano email: sebabuti@libero.it, sebabuti@libero.it organization: Department of Medicine and Surgery, University of Parma, Parma, Italy. sebabuti@libero.it – sequence: 5 givenname: Giuseppe surname: Procopio fullname: Procopio, Giuseppe organization: Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Italy – sequence: 6 givenname: Ugo surname: De Giorgi fullname: De Giorgi, Ugo organization: Medical Oncology Department, IRCCS Istituto Romagnolo per lo studio dei tumori (IRST) "Dino Amadori", Meldola, Italy – sequence: 7 givenname: Sandro surname: Pignata fullname: Pignata, Sandro organization: Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy – sequence: 8 givenname: Emanuele surname: Naglieri fullname: Naglieri, Emanuele organization: U.O. Oncologia, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy – sequence: 9 givenname: Marco surname: Maruzzo fullname: Maruzzo, Marco organization: IOV - IRCCS, Oncologia 1, Istituto Oncologico Veneto, Padova, Italy – sequence: 10 givenname: Giuseppe Luigi surname: Banna fullname: Banna, Giuseppe Luigi organization: Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, PO1 2UP, UK – sequence: 11 givenname: Pasquale surname: Rescigno fullname: Rescigno, Pasquale organization: Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy – sequence: 12 givenname: Carlo surname: Messina fullname: Messina, Carlo organization: Oncology Unit, ARNAS Civico, Palermo, Italy – sequence: 13 givenname: Alvise surname: Mattana fullname: Mattana, Alvise organization: IOV - IRCCS, Oncologia 1, Istituto Oncologico Veneto, Padova, Italy – sequence: 14 givenname: Umberto surname: Basso fullname: Basso, Umberto organization: IOV - IRCCS, Oncologia 1, Istituto Oncologico Veneto, Padova, Italy – sequence: 15 givenname: Davide surname: Bimbatti fullname: Bimbatti, Davide organization: IOV - IRCCS, Oncologia 1, Istituto Oncologico Veneto, Padova, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38914928$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkl1v0zAYhSM0xD7gD3CBLCGh7SLDdpzavpqqaYxKRZMKu7Yc22lTJfGwHUYv-ee8bcdoEMpFktfPOZaPz2l21PveZdlbgi8JEZOPkVAhyhxTlhNaEJmTF9kJYZzklGF-dPB9nJ3GuMaYcIHFq-y4EJIwScVJ9mvWJxd6nRrf6xZ1Q5sa47YzFJxu80cfWosWN7dNTGGDah_QA8BARPTYpBXqXNIxwciAoJ_OkXFti4wOpul9p1GOvjiX8vvFHSoKFNNgN-gc_IDc_Vy8zl7Wuo3uzdP7LLv_dPPt-nM-v7udXU_nuSkJTnlZVZJMHGMVsxUtnZwIibGuZKGFM3VhpaWFnZQCc8wKqRnjFGtmnLMG13VVnGWzva_1eq0eQtPpsFFeN2o38GGpdIBjtE5hXlfSEgjJWSZqITjXDGwkdbRytgavq73Xw1B1sAHEEXQ7Mh2v9M1KLf0PRQiREHwJDudPDsF_H1xMqmviNjrdOz9EVWBOpJR8IgF9_w-69gNcWbujJBFc8MlfaqnhBE1fe9jYbE3VlEuJacmYAOryPxQ81nWNgXrVDcxHgouRAJjkfqalHmJUs6-LMfvhgF1BfdIq-nbYdiuOQboHTfAxBlc_J0ew2lZb7autoNpqV21FQPTuMPNnyZ8uF78B3tTzsg |
| Cites_doi | 10.1056/NEJMoa1510665 10.1016/j.ejca.2021.06.015 10.1016/j.ctrv.2022.102377 10.1007/s11523-019-00653-5 10.1177/17588359211019642 10.1016/j.ejca.2020.05.009 10.1016/j.ctrv.2021.102295 10.3390/cancers12010143 10.1016/j.euo.2021.03.001 10.1016/S1470-2045(23)00049-9 10.1007/s00262-020-02684-8 10.1016/S1470-2045(22)00290-X 10.1016/j.annonc.2020.11.016 10.1002/cncr.33033 10.1016/j.euo.2019.06.022 10.1016/S1470-2045(20)30436-8 10.1200/OP.21.00419 10.1177/1758835920907504 10.1016/j.critrevonc.2022.103881 10.1136/esmoopen-2020-001079 10.1016/j.hoc.2023.04.017 10.1136/bmj-2022-071108 10.1056/NEJMoa1816714 |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 |
| Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12885-024-12319-1 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Science in Context ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 5 |
| ExternalDocumentID | oai_doaj_org_article_07fb9d1891ed48f8877a4dc092e2bedf A799025448 10_1186_s12885_024_12319_1 38914928 |
| Genre | Multicenter Study Journal Article Observational Study |
| GeographicLocations | Italy |
| GeographicLocations_xml | – name: Italy |
| GroupedDBID | --- -A0 0R~ 23N 2WC 3V. 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS ECM EIF EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 LGEZI LOTEE M1P M48 M~E NADUK NPM NXXTH O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX CITATION AFGXO ABVAZ 7TO 7XB 8FK AZQEC DWQXO H94 K9. PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c510t-5bb916e44b4db25e968900ab93a8ecf3d9d23d658070439a44720a4ceedc0ffb3 |
| IEDL.DBID | RPM |
| ISSN | 1471-2407 |
| IngestDate | Tue Oct 22 15:14:50 EDT 2024 Tue Sep 17 21:28:45 EDT 2024 Sat Oct 26 02:08:20 EDT 2024 Thu Oct 10 22:16:07 EDT 2024 Wed Jul 03 17:11:19 EDT 2024 Tue Jul 02 03:50:46 EDT 2024 Sat Sep 28 21:20:52 EDT 2024 Tue Aug 20 22:16:39 EDT 2024 Thu Sep 12 21:06:05 EDT 2024 Sat Nov 02 12:08:00 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Metastatic renal cell carcinoma Prospective IMDC score Immune checkpoint inhibitor Meet-URO score Immunotherapy Real-world Clinical practice Retrospective |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c510t-5bb916e44b4db25e968900ab93a8ecf3d9d23d658070439a44720a4ceedc0ffb3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11194925/ |
| PMID | 38914928 |
| PQID | 3079187876 |
| PQPubID | 44074 |
| PageCount | 5 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_07fb9d1891ed48f8877a4dc092e2bedf pubmedcentral_primary_oai_pubmedcentral_nih_gov_11194925 proquest_miscellaneous_3071999769 proquest_journals_3079187876 gale_infotracmisc_A799025448 gale_infotracacademiconefile_A799025448 gale_incontextgauss_ISR_A799025448 gale_healthsolutions_A799025448 crossref_primary_10_1186_s12885_024_12319_1 pubmed_primary_38914928 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-06-24 |
| PublicationDateYYYYMMDD | 2024-06-24 |
| PublicationDate_xml | – month: 06 year: 2024 text: 2024-06-24 day: 24 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2024 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | 12319_CR15 P Lombardi (12319_CR14) 2022; 106 12319_CR16 L Albiges (12319_CR8) 2020; 5 RJ Motzer (12319_CR11) 2022; 23 AA Matthews (12319_CR20) 2022; 378 TK Choueiri (12319_CR12) 2023; 24 F Massari (12319_CR23) 2021; 154 R Garje (12319_CR4) 2020; 12 SE Rebuzzi (12319_CR19) 2021; 13 G de Velasco (12319_CR3) 2019; 2 BA McGregor (12319_CR18) 2020; 135 M Moran (12319_CR2) 2019; 14 RJ Motzer (12319_CR5) 2015; 373 T Powles (12319_CR21) 2021; 32 K Mori (12319_CR22) 2021; 70 RJ Motzer (12319_CR6) 2020; 126 J Tran (12319_CR13) 2022; 18 MD Delcuratolo (12319_CR17) 2023; 181 T Powles (12319_CR9) 2020; 21 E Rassy (12319_CR1) 2020; 12 F Quhal (12319_CR7) 2021; 4 BI Rini (12319_CR10) 2019; 380 |
| References_xml | – volume: 373 start-page: 1803 issue: 19 year: 2015 ident: 12319_CR5 publication-title: N Engl J Med doi: 10.1056/NEJMoa1510665 contributor: fullname: RJ Motzer – volume: 154 start-page: 120 year: 2021 ident: 12319_CR23 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2021.06.015 contributor: fullname: F Massari – volume: 106 start-page: 102377 year: 2022 ident: 12319_CR14 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2022.102377 contributor: fullname: P Lombardi – volume: 14 start-page: 405 year: 2019 ident: 12319_CR2 publication-title: Target Oncol doi: 10.1007/s11523-019-00653-5 contributor: fullname: M Moran – volume: 13 start-page: 175883592110196 year: 2021 ident: 12319_CR19 publication-title: Ther Adv Med Oncol doi: 10.1177/17588359211019642 contributor: fullname: SE Rebuzzi – volume: 135 start-page: 203 year: 2020 ident: 12319_CR18 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2020.05.009 contributor: fullname: BA McGregor – ident: 12319_CR15 doi: 10.1016/j.ctrv.2021.102295 – volume: 12 start-page: 143 issue: 1 year: 2020 ident: 12319_CR4 publication-title: Cancers (Basel) doi: 10.3390/cancers12010143 contributor: fullname: R Garje – volume: 4 start-page: 755 issue: 5 year: 2021 ident: 12319_CR7 publication-title: Eur Urol Oncol doi: 10.1016/j.euo.2021.03.001 contributor: fullname: F Quhal – volume: 24 start-page: 228 issue: 3 year: 2023 ident: 12319_CR12 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(23)00049-9 contributor: fullname: TK Choueiri – volume: 70 start-page: 265 issue: 2 year: 2021 ident: 12319_CR22 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-020-02684-8 contributor: fullname: K Mori – volume: 23 start-page: 888 issue: 7 year: 2022 ident: 12319_CR11 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(22)00290-X contributor: fullname: RJ Motzer – volume: 32 start-page: 422 year: 2021 ident: 12319_CR21 publication-title: Ann Oncol doi: 10.1016/j.annonc.2020.11.016 contributor: fullname: T Powles – volume: 126 start-page: 4156 year: 2020 ident: 12319_CR6 publication-title: Cancer doi: 10.1002/cncr.33033 contributor: fullname: RJ Motzer – volume: 2 start-page: 505 issue: 5 year: 2019 ident: 12319_CR3 publication-title: Eur Urol Oncol doi: 10.1016/j.euo.2019.06.022 contributor: fullname: G de Velasco – volume: 21 start-page: 1563 issue: 12 year: 2020 ident: 12319_CR9 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30436-8 contributor: fullname: T Powles – volume: 18 start-page: 187 issue: 3 year: 2022 ident: 12319_CR13 publication-title: JCO Oncol Pract doi: 10.1200/OP.21.00419 contributor: fullname: J Tran – volume: 12 start-page: 175883592090750 year: 2020 ident: 12319_CR1 publication-title: Ther Adv Med Oncol doi: 10.1177/1758835920907504 contributor: fullname: E Rassy – volume: 181 start-page: 103881 year: 2023 ident: 12319_CR17 publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2022.103881 contributor: fullname: MD Delcuratolo – volume: 5 start-page: e001079 issue: 6 year: 2020 ident: 12319_CR8 publication-title: ESMO Open doi: 10.1136/esmoopen-2020-001079 contributor: fullname: L Albiges – ident: 12319_CR16 doi: 10.1016/j.hoc.2023.04.017 – volume: 378 start-page: e071108 year: 2022 ident: 12319_CR20 publication-title: BMJ doi: 10.1136/bmj-2022-071108 contributor: fullname: AA Matthews – volume: 380 start-page: 1116 issue: 12 year: 2019 ident: 12319_CR10 publication-title: N Engl J Med doi: 10.1056/NEJMoa1816714 contributor: fullname: BI Rini |
| SSID | ssj0017808 |
| Score | 2.4700835 |
| Snippet | Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the... Abstract Background Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC).... Background Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations... BackgroundNowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 757 |
| SubjectTerms | Aged Antimitotic agents Antineoplastic agents Carcinoma, Renal cell Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - mortality Carcinoma, Renal Cell - pathology Care and treatment Clinical medicine Clinical practice Consent Data collection Decision making Development and progression Diagnosis Disease control Dosage and administration Drug therapy Female Health aspects Histology Humans IMDC score Immune checkpoint inhibitor Immunotherapy Kidney cancer Kidney Neoplasms - drug therapy Kidney Neoplasms - mortality Kidney Neoplasms - pathology Leukocytes (neutrophilic) Lymphocytes Male Medical prognosis Medical research Medicine, Experimental Metastases Metastasis Metastatic renal cell carcinoma Middle Aged Observational studies Patients Prognosis Prospective Studies Real-world Registries Regulatory approval Renal cell carcinoma Retrospective Studies Study Protocol Toxicity |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQD4gLovyGFjAICRCK6jjexD4uqKUgFqSFlXqzbMemldosarJ3JB6hb8iTdMbJrtbiwIVj1hMrO_-2Zz4T8pI7X4hQNHnNAsuFq1RuhQGBBFVYL0rBHJ7ozr5Uxwvx6WRysnXVF9aEDfDAA-MOWB2sagqpCt8IGcAmaiMaxxT33PomRO_L1HoxNZ4f1JLJdYuMrA468MISO5ERow_bdookDEW0_r998lZQSgsmtyLQ0R1ye0wd6XT45F1yw7d3yc3ZeDh-j_xOdvdoLBXEqfwlhczwPI_gqHR--CFe8EYhW6UjqmpHcTuWXvjeYIPRmYMX2ulnirv61OFtQ-3ywtA_v67ozPs-X8y_0rKkEZqWvoYZgTY-vLlPFkeH398f5-MdC7kDa-zzibWQIHohrGgsn3hVScWYsao00rtQNqrhZQNpCrgGyF2MEDVnRmBodSwEWz4gO-2y9Y8I9QrxnAxEPxsErNGNtaVTQMql497wjLxds1z_HKA0dFyCyEoPAtIgIB0FpIuMvEOpbCgRBjv-AMqhR-XQ_1KOjDxDmeqhp3RjzHpaKxXB2WRGXkQKhMJosdbmh1l1nf74bZ4QvRqJwhLk78zYugD_G9GzEsr9hBJs1aXDa-XSo6_oNHhZVUhwnFVGnm-G8U2sf2v9chVpEC-irlRGHg66uOEMnjQLxWFymWhpwrp0pD07jUjiEOgUolM-_h_M3iO3OFoYq3Iu9slOf7nyTyBj6-3TaJzXgqo_rA priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fb9MwELdgSIgXxH8yBhiEBAhFcxw3sZ9QQRsDUZAKlfpm2Y49JrFka9p3JD4C35BPwp3rlkVIPLa-WInvr893PxPyjDtfiFA0ec0Cy4WrVG6FAYYEVVgvSsEcnuhOPlVHM_FhPpqnhFufyio3NjEa6qZzmCPfB1lUhQTxql6fned4axSerqYrNC6TKwVnFZZ01fPthquoJZObRhlZ7fdgiyX2IyNSHzbvFANnFDH7_7XMF1zTsGzygh86vEGupwCSjtccv0ku-fYWuTpJR-S3yc9Bjo_GgkGcyi8oxIff8wiRSqcH7-I1bxRiVpqwVXuKSVl66pcG24xOHDzQjj9SzO1Th3cOtd2pob9__KIT75f5bPqZliWNALX0BcwItPHHyztkdnjw9e1Rnm5ayB3o5DIfWQthohfCisbykVeVVIwZq0ojvQtloxpeNhCsgIGACMYIUXNmBDpYx0Kw5V2y03atv0-oV4jqZMAH2iBgp26sLZ0CUi4d94Zn5NVmyfXZGlBDx42IrPSaQRoYpCODdJGRN8iVLSWCYcc_usWxTrqlWR2sagqpCt8IGcBs1kbAiynuufVNyMhj5Kled5ZuVVqPa6UiRJvMyNNIgYAYLVbcHJtV3-v3X6YDoueJKHTAf2dSAwN8N2JoDSj3BpSgsW44vBEunSxGr__Kd0aebIfxSayCa323ijSIGlFXKiP31rK4XRk8bxaKw-RyIKWDpRuOtCffIp44uDuFGJW7_3-vB-QaR91hVc7FHtlZLlb-IURkS_soqt0feao2Qg priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEA_HCeKL-G311CiCD1Jt02ybPIiscucprsLqwr2FJE3uDu5a3XZB_3tn0na94D342kxDO5P5SCbzG0KeM-ty7vM6rTKfpdyWMjVcg0C8zI3jBc8sZnQXX8rDFf90NDvaIVO7o5GB3aVbO-wntVqfvfr18_dbUPg3QeFF-boDGyuwzhgR-LAoB3ZDVxiHnTpe5eN_swqVCB3qcjDImFWopiKaS-eIHFXA8__Xal9wW_GVygs-6uAGuT4Gl3Q-rIabZMc1t8jVxZg-v0266PyPhsuEOJVbU4gdz9IAn0qX-x9CCzgK8SwdcVc7ige29Nz1GkuQTi280Mw_Uzz3pxb7ETXtuaYpXTjXp6vlV1oUNEDX3iGrg_3v7w_TsetCakE_-3RmDISMjnPDa8NmTpZCZpk2stDCWV_UsmZFDYELGAuIZjTnFcs0R2drM-9NcZfsNm3j7hPqJCI8afCHxnPYtWtjCiuBlAnLnGYJeTmxWP0YwDVU2JSIUg0CUSAQFQSi8oS8QylsKREYOzxo18dq1DOVVd7IOhcydzUXHkxopTl8mGSOGVf7hDxBGaqhynSr3mpeSRng2kRCngUKBMdo8PbNsd50nfr4bRkRvRiJfAvytnosZoD_RjytiHIvogTttfHwtJjUtPgV2F2ZCzClZUKebofxTbwR17h2E2gQQaIqZULuDWtvyxnMPXPJYHIRrcqIdfFIc3oSsMXB9UnEq3zwP1x4SK4x1JisBHXaI7v9euMeQYzWm8dB8f4Al143LQ priority: 102 providerName: Scholars Portal |
| Title | International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study) |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38914928 https://www.proquest.com/docview/3079187876 https://www.proquest.com/docview/3071999769 https://pubmed.ncbi.nlm.nih.gov/PMC11194925 https://doaj.org/article/07fb9d1891ed48f8877a4dc092e2bedf |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa2ISFeEHcCoxiEBAhlTRw3sR_bqWMgOqZCpWovlu3Yo9KaTr28I_ET-If8Es5xk2oRb7xEan1sJT5X2-d8JuQNsy7lPi3jIvFJzG0uY8M1MMTL1Die8cTiie7oLD-d8M_T3nSP5E0tTEjat2Z2VF3Nj6rZj5BbeT233SZPrHs-Ogb9lAiq190n-yChzRq9PjsoRCKa8hiRd1dggQVWISM-H5bspC0XFJD6_7XHNxxSO1nyhvc5uUfu1mEj7W9f7z7Zc9UDcntUH4w_JL9aO3s0pAniUG5JISq8igMwKh0PP4bL3ShEqrRGVF1R3Iqlc7fWWFw0s9Ch6n-huKNPLd40VC3mmv75-ZuOnFvHk_FXmmU0wNLSdzAi0IYf7x-Rycnw-_FpXN-vEFvQxHXcMwaCQ8e54aVhPSdzIZNEG5lp4azPSlmyrIQQBcwCxC2a84IlmqNbtYn3JntMDqpF5Z4S6iRiOWnwfMZzWJ9rYzIrgZQJy5xmEfnQTLm63sJoqLD8ELnaMkgBg1RgkEojMkCu7CgRAjv8sVheqloQVFJ4I8tUyNSVXHgwloXm8GKSOWZc6SPyEnmqtvWkO0VW_ULKAMwmIvI6UCAMRoV5Npd6s1qpT9_GLaK3NZFfAP-trssW4LsROatFediiBD217eZGuFRtJ1YKLKxMBRjNPCKvds3YE3PfKrfYBBrEiihyGZEnW1nczQyeMoMmwOCiJaWtqWu3gFIFFPFGiZ79f9fn5A5DvUrymPFDcrBebtwLiNHWpgOKOS065NZgeHY-7oSdDniOuIDneHDRCSr7F-O9Qyo |
| link.rule.ids | 230,315,730,783,787,867,888,2109,2228,12068,21400,24330,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fb9MwELdgk4AXxH8CgxmEBAhFSxw3sZ9Qhzo6aAsqq7Q3y3acbdKWjKZ9R-Ij8A35JNy5blmExGPri5X4_vrO9zMhr5h1Ka_SMi6SKom5zWVsuAaGVDI1jmc8sVjRHU_y4Yx_Ou4dh4RbG45Vrm2iN9RlYzFHvgeyKFMB4pW_v_we461RWF0NV2hcJ9sIVQWbr-39weTrdFNHKEQi1q0yIt9rwRoL7EhGrD5s30k77sij9v9rm684p-7BySue6OAOuR1CSNpf8fwuuebqe-TGOBTJ75OfnSwf9UcGcSo3pxAhnsceJJVOBx_9RW8UolYa0FVbimlZeuEWGhuNziw8UPdHFLP71OKtQ3VzoenvH7_o2LlFPJt-oVlGPUQtfQMzAq3_8fYBmR0Mjj4M43DXQmxBKxdxzxgIFB3nhpeG9ZzMhUwSbWSmhbNVVsqSZSWEK2AiIIbRnBcs0RxdrE2qymQPyVbd1O4xoU4irpMGL2gqDnt1bUxmJZAyYZnTLCLv1kuuLleQGspvRUSuVgxSwCDlGaTSiOwjVzaUCIft_2jmJypol0qKysgyFTJ1JRcVGM5Cc3gxyRwzrqwisos8Vave0o1Sq34hpQdpExF56SkQEqPGMzcnetm26vDbtEP0OhBVDfDf6tDCAN-NKFodyp0OJeis7Q6vhUsFm9GqvxIekRebYXwSz8HVrll6GsSNKHIZkUcrWdysDFacuWQwuehIaWfpuiP12alHFAeHJxGl8sn_32uX3BwejUdqdDj5_JTcYqhHSR4zvkO2FvOlewbx2cI8D0r4B3B7Opg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgSBMv3C-BwQxCAoTS5uIm9mMZKxusYypUmsSDZTv2qFjTqklfeELiJ_AP-SUcO061wNseW3-OnJyLT3LO-YzQi0TpmJi4CPPIRCFRGQslESAQw2KpSUoiZTO64-PsYEo-nA5OfVVl5csqSyVnvfJ83itn31xt5XKu-m2dWP9kvAf2ySypXn9ZmP5VdA2MNsraN3WfQchpRNsmGZr1K_DD1PYiW5Y-27gTdzYix9f_v1e-sC11SyYv7EGjm-hru_qm9OR7b13LnvrxD7Hj5W7vFrrhQ1M8bDC30RVd3kHbY598v4t-db4eYleKaBeqVxgiz_PQka_iyf57d4AchmgYe9bWCtvPvXiua2EbmGYKJpTDI2yzBljZ04zKxVzgPz9_47HWdTidfMJpih31LX4FVwSs-_H6HpqO9r_sHYT-DIdQgbXX4UBKCEA1IZIUMhlollEWRUKyVFCtTFqwIkkLCIPA9UBsJAjJk0gQu3WryBiZ3kdb5aLUDxHWzPJFCdhdpSFapkLKVDGAJlQlWiQBetMKlC8bqg7uXnFoxhvxcxA_d-LncYDeWplvkJZm2_2xWJ1xLw0e5UayIqYs1gWhBhxyLggsjCU6kbowAdq1GsObntWNs-DDnDFH_kYD9NwhLNVGaWt5zsS6qvjh50kH9NKDzAK0SwnfGgH3bdm5OsidDhJ8geoOt6rLvS-qOHhxFlNwzFmAnm2G7UxbX1fqxdphLB9FnrEAPWg0ffNkbCYb1BEuTjs20Hl03RHQbMdU3mryo8tP3UXbJ-9G_Ojw-ONjdD2xBhxlYUJ20Fa9WusnEBLW8qmz_b8jKWJy |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=International+multicenter+real-world+REGistry+for+patients+with+metastatic+renAL+cell+carcinoma+-+Meet-URO+33+study&rft.jtitle=BMC+cancer&rft.au=Rebuzzi%2C+Sara+Elena&rft.au=Fornarini%2C+Giuseppe&rft.au=Signori%2C+Alessio&rft.au=Buti%2C+Sebastiano&rft.date=2024-06-24&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=24&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-024-12319-1&rft.externalDBID=ISR&rft.externalDocID=A799025448 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |